Silexion Therapeutics Corp (SLXN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Silexion Therapeutics reported revenue of $155,000, up 453.6% from $28,000 the year before. Net income was -$11.9M (a -7685.2% net margin), or $89.60 per diluted share. Operating margin was -7504.5%. Operating activities generated -$10.8M of cash, leaving -$10.8M of free cash flow. At fiscal year end, Silexion Therapeutics held $7.2M in total assets against $4.6M in total liabilities, including $6.0M of cash and equivalents.
Open the full interactive Silexion Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Silexion Therapeutics Key Stats
| Share Price | $0.18 |
|---|---|
| Market Cap | $120,974 |
| P/E Ratio | 0.0 |
| Revenue YoY Growth | +453.6% |
| 52-Week Range | $0.18 – $37.80 |
| Shares Outstanding | 687,353 (basic, 2026 Q2) |
Silexion Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $28,000 | $155,000 |
| Operating Income | -$12.6M | -$11.6M |
| Pre-Tax Income | -$16.5M | -$11.9M |
| Income Tax | $10,000 | $3,000 |
| Net Income | -$16.5M | -$11.9M |
| Diluted EPS | $3954.00 | $89.60 |
Silexion Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $39,000 | $70,000 | $32,000 | $14,000 |
| Net Income | -$3.3M | -$4.4M | -$2.7M | -$3.6M |
| Diluted EPS | $28.80 | -$3.32 | $8.50 | $5.17 |
Silexion Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $1.2M | $6.0M |
| Current Assets | $2.2M | $6.6M |
| Total Assets | $2.9M | $7.2M |
| Current Liabilities | $3.5M | $2.8M |
| Total Liabilities | $6.9M | $4.6M |
| Shareholders' Equity | -$4.0M | $2.6M |
Silexion Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$8.4M | -$10.8M |
| Cash From Investing | -$22,000 | -$14,000 |
| Cash From Financing | $5.1M | $15.6M |
| Free Cash Flow | -$8.4M | -$10.8M |
Figures from Silexion Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Silexion Therapeutics financials page for every line item.
Silexion Therapeutics Company Profile
| Ticker | SLXN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Ramat Gan, Israel |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002022416 |
Frequently Asked Questions
What was Silexion Therapeutics' revenue in fiscal 2025?
Silexion Therapeutics (SLXN) reported revenue of $155,000 for fiscal 2025.
What was Silexion Therapeutics' net income in fiscal 2025?
Silexion Therapeutics reported net income of -$11.9M for fiscal 2025.
What was Silexion Therapeutics' earnings per share (EPS) in fiscal 2025?
Silexion Therapeutics' diluted EPS was $89.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Silexion Therapeutics generate in fiscal 2025?
Silexion Therapeutics generated -$10.8M of free cash flow in fiscal 2025.
What was Silexion Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Silexion Therapeutics reported revenue of $14,000.
How many shares of Silexion Therapeutics are outstanding?
Silexion Therapeutics reported a weighted average of 687,353 basic shares outstanding in 2026 Q2.
What is Silexion Therapeutics' market cap?
Based on its latest closing price, Silexion Therapeutics (SLXN) has a market capitalization of about $120,974.
When does Silexion Therapeutics' fiscal year end?
Silexion Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Silexion Therapeutics headquartered?
Silexion Therapeutics lists its business address in Ramat Gan, Israel in its SEC filings.
Silexion Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →